Flow goes forward and cells step backward: endothelial migration

HW Lee, JH Shin, M Simons - Experimental & Molecular Medicine, 2022 - nature.com
Systemic and pulmonary circulations constitute a complex organ that serves multiple
important biological functions. Consequently, any pathological processing affecting the …

Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases

P Lanzetta, A Loewenstein… - Graefe's Archive for …, 2017 - Springer
Background Intravitreal anti–vascular endothelial growth factor (VEGF) therapy is now
considered the gold standard for the treatment of various retinal disorders. As therapy has …

Critical analysis of techniques and materials used in devices, syringes, and needles used for intravitreal injections

GB Melo, NFS da Cruz, GG Emerson… - Progress in Retinal and …, 2021 - Elsevier
Intravitreal injections have become the most commonly performed intraocular treatments
worldwide. Because intravitreal injections may induce severe adverse events, such as …

Reverse engineering the Ozurdex dexamethasone intravitreal implant

MA Costello, J Liu, Y Wang, B Qin, X Xu, Q Li… - International Journal of …, 2023 - Elsevier
Ozurdex is a biodegradable implant formulated for sustained-release delivery of the
corticosteroid dexamethasone to the posterior segment of the eye. The small, rod-shaped …

Gold nanoparticles in ophthalmology

F Masse, M Ouellette, G Lamoureux… - Medicinal research …, 2019 - Wiley Online Library
Many research projects are underway to improve the diagnosis and therapy in
ophthalmology. Indeed, visual acuity deficits affect 285 million people worldwide and …

The effect of anti-vascular endothelial growth factor agents on intraocular pressure and glaucoma: a report by the American Academy of Ophthalmology

A Hoguet, PP Chen, AK Junk, P Mruthyunjaya… - Ophthalmology, 2019 - Elsevier
Purpose To assess the effect of intravitreal injections of anti-vascular endothelial growth
factor (VEGF) agents on immediate and long-term intraocular pressure (IOP) elevation and …

Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and …

S Sangroongruangsri, T Ratanapakorn… - Expert review of …, 2018 - Taylor & Francis
Introduction: Anti-vascular endothelial growth factor (VEGF) therapy has become the most
commonly used treatment for macular edema secondary to retinal vein occlusion (RVO) …

Cost-effectiveness and cost-utility of traditional and telemedicine combined population-based age-related macular degeneration and diabetic retinopathy screening in …

R Li, Z Yang, Y Zhang, W Bai, Y Du, R Sun… - The Lancet Regional …, 2022 - thelancet.com
Background To assess the cost-effectiveness and cost-utility of a population-level traditional
and telemedicine combined age-related macular degeneration (AMD) and diabetic …

Recent advances in ocular drug delivery systems and targeting VEGF receptors for management of ocular angiogenesis: A comprehensive review

S Narayana, MG Ahmed, BHJ Gowda… - Future Journal of …, 2021 - Springer
Background Angiogenic ocular diseases address the main source of vision impairment or
irreversible vision loss. The angiogenesis process depends on the balance between the pro …

[HTML][HTML] Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity

KD Beharry, GB Valencia, DR Lazzaro… - Seminars in …, 2016 - Elsevier
Retinopathy of prematurity (ROP), a significant morbidity in prematurely born infants, is the
most common cause of visual impairment and blindness in children and persists till …